DDX53 and colorectal carcinoma: We found that the combined treatment of 5FU+Rapamycin had a stronger inhibitory effect on CT26 cell proliferation than 5FU treatment alone (Figure 5C), indicating that mTOR activation mediates resistance to 5FU therapy for CRC.